Trk Receptor
Tropomyosin related kinase receptor
Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).
TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.
The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.
Trk Receptor Isoform Specific Products
All Product Categories
-
Trk Receptor Inhibitors
(147)
View all products
-
Trk Receptor Agonists
(13)
View all products
-
Trk Receptor Antagonists
(4)
View all products
-
Trk Receptor Activators
(24)
View all products
-
Trk Receptor Modulators
(4)
View all products
-
Trk Receptor Degraders
(5)
View all products
-
Trk Receptor Controls
(4)
View all products
-
Trk Receptor Ligands
(2)
View all products
-
Trk Receptor Related Products (219)
Related Products (219)
-
Antibodies (9)
-
Trk Receptor Isoform Comparison
-
TRK-IN-30
0 ImagesCat. No.: HY-168858TRK-IN-30 (Compound C11) is the inhibitor for tropomyosin receptor kinase (TRK) that inhibits TRKA, TRKB and TRKC and drug resistant mutant TRKAG595R with an IC50 of 1.8, 0.98, 3.8, and 54 nM, respectively. TRK-IN-30 inhibits the activation of the downstream PI3K/AKT and MEK/ERK signaling pathways. TRK-IN-30 inhibits the colony formation and cell migration of Km-12, arrests the cell cycle at G0/G1 phase, and induces apoptosis in Km-12.
-
TrkA-IN-6
0 ImagesCat. No.: HY-157168TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC50 of 68.99 μM.
-
TRK-IN-24
0 ImagesCat. No.: HY-156086CAS No.: 2937544-01-7TRK-IN-24 (compound 10g) is a Trk Receptor inhibitor that inhibits TRKA, TRKC, TRKAG595R, TRKAG667C and TRKAF589L IC50s are 5.21, 4.51, 6.77, 1.42 and 6.13 nM respectively. TRK-IN-24 has antitumor efficacy in BaF3-CD74-NTRK1G595R and BaF3-CD74-NTRK1G667C xenograft models. TRK-IN-24 inhibits the proliferation of Ba/F3 cells transfected with single mutants such as SF, GK, and xDFG, with an IC50 of 1.43-47.56 nM.
-
Levomilnacipran
0 ImagesCat. No.: HY-14794ACAS No.: 96847-54-0Synonyms: (1S,2R)-Milnacipran; F2695Levomilnacipran ((1S,2R)-Milnacipran) is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression.
-
KRC-108
0 ImagesCat. No.: HY-123237CAS No.: 1146944-35-5KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice.
-
TRK-IN-31 hydrochloride
0 ImagesCat. No.: HY-174330ATRK-IN-31 hydrochloride is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 hydrochloride has superior antiproliferative activity in the Ba/F3-MPRIP-TRKAG667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 hydrochloride significantly inhibits tumor growth in Ba/F3-MPRIP-TRKAG667C subcutaneous tumor mice model.
-
TRK-IN-29
0 ImagesCat. No.: HY-161819TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC50: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKAG595R, TRKAF589L, TRKAG667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties.
-
Trk-IN-7
0 ImagesCat. No.: HY-143557CAS No.: 2383011-61-6
-
Inonophenol C
0 ImagesCat. No.: HY-145105CAS No.: 3017174-74-9Inonophenol C is a neurotrophic and protective agent against neurodegenerative disorders.
-
PROTAC NTRK1 degrader-1
0 ImagesCat. No.: HY-181052CAS No.: 2922274-35-7PROTAC NTRK1 degrader-1 is a wild-type and mutant NTRK1 PROTAC degrader with IC50 values of 4 nM (wild-type), 2 nM (G595R), 5 nM (G667C), and <0.5 nM (F598L). PROTAC NTRK1 degrader-1 catalyzes ubiquitination and subsequent proteasome-mediated degradation of wild-type and mutant (G595R, G667C, F598L) NTRK1. PROTAC NTRK1 degrader-1 can be used for the research of solid tumors.
-
Polygalasaponin XXXII
0 ImagesCat. No.: HY-N20637CAS No.: 176182-04-0Polygalasaponin XXXII is an orally active cognitive enhancer. Polygalasaponin XXXII promotes the phosphorylation of ERK, CREB, Synapsin I and TrkB. Polygalasaponin XXXII enhances basal synaptic transmission. Polygalasaponin XXXII attenuates Scopolamine (HY-N0296)-induced cognitive impairment and improves hippocampus-dependent learning and memory abilities. Polygalasaponin XXXII can be used in research related to cognitive dysfunction.
-
Levomilnacipran-d10 hydrochloride
0 ImagesCat. No.: HY-14794ASCAS No.: 2747914-23-2Synonyms: (1S,2R)-Milnacipran-d10 hydrochloride; F2695-d10 hydrochlorideLevomilnacipran-d10 ((1S,2R)-Milnacipran-d10) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression.
-
TRK/ALK-IN-1
0 ImagesCat. No.: HY-144732CAS No.: 3052405-64-5TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of TRK and ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC50 values of 2.2, 9.3 and 38 nM towards TRKA, ALKWT and ALKL1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases.
-
MEDI-7352
0 ImagesCat. No.: HY-P991324MEDI-7352 is a human bispecific antibody (bsAb) targeting NGF/bNGF & TNF. MEDI-7352 can be used in osteoarthritis (OA) pain research.
-
NS 1231
0 ImagesCat. No.: HY-165616CAS No.: 309711-72-6NS 1231 is a neurotrophic-like compound with neuroprotective effect. NS 1231 can rescue nerve growth factor (NGF)-differentiated PC12 cells from death induced by withdrawal of trophic factors. NS 1231 can stimulate NGF-induced neurite outgrowth of undifferentiated PC12 cells. NS 1231 can be used for the research of neurological disease, such as stroke.
-
JWJ-01-378
0 ImagesCat. No.: HY-175271JWJ-01-378 is a selective TRK PROTAC degrader. JWJ-01-378 efficiently degrades WT TRK and TPM3-TRKA fusion proteins and inhibits downstream pERK signaling, while showing limited efficacy against TRK inhibitor resistant mutants and ALK fusions. JWJ-01-378 potently suppresses cancer cell proliferation.Pink: TRK ligand (HY-160520); Blue: CRBN ligase ligand (HY-103596); Black: linker
-
Type II TRK inhibitor 3
0 ImagesCat. No.: HY-174161Type II TRK inhibitor 3 (Compound 18d) is a Type II TRK inhibitor with IC50 values of 0.82, 1.82, and 0.12 nM for TRKAWT/G595R/G667C, respectively. Type II TRK inhibitor 3 exhibits antitumor activity.
-
Type II TRK inhibitor 2
0 ImagesCat. No.: HY-163004Type II TRK inhibitor 2 (compound 40l) is a selective type II TRK inhibitor with plasma stability and moderate hepatic microsomal stability. Type II TRK inhibitor 2 significantly inhibits Km-12, Ba/F3-TRKAG595R and Ba/F3-TRKAG667C cell proliferation (IC50: 4.1 nM, 41.5 nM, 1.4 nM). Type II TRK inhibitor 2 can be used to study NTRK fusion cancers.
-
TrkB activator-1
0 ImagesCat. No.: HY-175483SCAS No.: 3087336-56-6TrkB activator-1 is a specific, orally active and brain-penetrant tropomyosin receptor kinase B (TrkB) activator. TrkB activator-1 shows potent antidepressant effects through activation of the activates the BDNF (brainderived neurotrophic factor)-Tropomyosin-related kinase B (TrkB)-CREB (cAMP response element binding protein) signaling aixs. TrkB activator-1 increaes neuroplasticity. TrkB activator-1 can be used for the research of neurological disease, such as depression.
